It's just cash and risk management of Homm, nothing else. - on the other hand he stays without any stop loss (in contrast to other positions than CUV)
Could have exited whenever they changed their road to glory after FDA rejected their tanning baby drug.When I went into Epitan a couple of decades ago, I went in because of the tanning effect and supposed to stop Melanoma's......so explain to me what happened? Have I been dudded because I certainly feel so.
It will be 2 years, not 3 years. As much as we want the company to try and bring future fantasy into the stock now and raise the PE, we know they are on their own organic growth path.I can only hope that it will be achieved in the next 3 years
I agree, I’ve been thinking along similar lines regarding slow release. Too much ACTH can lead to complications i.e. Cushing’s disease, so the use of ACTH in such a fashion for existing MS patients to ease exacerbations seems an optimal way to go. But I’m dead set on afamelanotide being the primary drug for juvenile MS, mainly because it is the first disease in a line of neurodegenerative disorders Clinuvel hopes to treat IMO (e.g. AD, Parkinson’s and others). I haven’t caught up on research regarding ACTH in AD as an example, but in recent Google searches so far these neurodegenerative disorders are not something that normally appears in ACTH research, which I think points back to the limitations of ACTH and how overuse of the drug in the brain can potentially be harmful. (ACTH MC2R and Afamelanotide MC4R?)With neuacthel inst. and neuacthelle mod. they probably have a one time injection which releases the molecule over a period of 2-3 weeks for acute MS relapses or even longer for the long term treatment of MS
Perhaps that simply means it's the final indication they would submit to regulatory agencies for approval which would officially be on the label? At a certain point, off-label becomes a thing. Clinical trials or other data could support it's efficacy still, it's safety would already be widely accepted at that point, and it would be so widely used the price would probably have dropped quite a bit by that point.P.S. I believe Clinuvel said the new indication is the ‘final indication’ for Afamelanotide in the AGM presentation. I’m not sure what that means exactly, perhaps it’s the final medical field that will introduce a new indication from and then new indications introduced afterwards will be label extensions e.g. skin group, CNS group, and emergency events.